Venofer® (iron sucrose injection, USP) provides first-line IV iron therapy for the treatment of iron deficiency anemia (IDA) in adult and pediatric patients 2 years and older with chronic kidney disease (CKD).
The global Venofer (iron sucrose injection) market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Venofer (iron sucrose injection) volume and value at global level, regional level and company level. From a global perspective, this report represents overall Venofer (iron sucrose injection) market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Venofer (iron sucrose injection) in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Venofer (iron sucrose injection) manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
Luitpold Pharmaceuticals
...
Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India
Segment by Type
50 mg/2.5 mL
100 mg/5 mL
200 mg/10 mL
Segment by Application
Adult
Pediatric
Summary:
Get latest Market Research Reports on Venofer (iron sucrose injection). Industry analysis & Market Report on Venofer (iron sucrose injection) is a syndicated market report, published as Global Venofer (iron sucrose injection) Market Professional Survey Report 2019. It is complete Research Study and Industry Analysis of Venofer (iron sucrose injection) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.